All In Biotech

Drug Trial Radar · NCT07590531

AMT-116 in Combination With AK112 in Patients With Lung Cancer

An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

May 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Conditions

  • Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions

  • AMT-116Drug

    AMT-116 is an antibody Drug Conjugate (ADC)

  • AK112Drug

    AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: To evaluate the safety and tolerability of the combination of AMT-116 and AK112 in patients with advanced NSCLC and to determine the recommended Phase 2 dose (RP2CD)Time frame: approximately 10 months
  2. Phase I: Type, incidence and severity of Adverse Events,Dose Limiting Toxicities (DLTs)Time frame: approximately 10 months
  3. Phase II: Objective Response Rate(ORR)Time frame: approximately 12 months
  4. Phase II: Type, incidence and severity of Adverse EventsTime frame: approximately 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhejiang cancer hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.